For second- and third-degree burns. Sold as Sulfamylon. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 15, 2026, FDA lists 4 applications for Mafenide Acetate (sold as Sulfamylon), first approved Jan 24, 1969, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Sulfamylon | Part D | $42K | -18% | 252 |
| Jan 24, 1969 | SulfamylonNDA 16763 · New active ingredient | Rising | 18 | Marketed |
| Jun 5, 1998 | SulfamylonNDA 19832 · New dosage form | Mylan Institutional | 8 | Discontinued |
| Feb 12, 2013 | Mafenide AcetateANDA 201511 | Ph Health | 0 | Discontinued |
| Jul 31, 2017 | Mafenide AcetateANDA 206716 | Ingenus Pharms LLC | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA